Key takeaways:
- Researchers introduced a brand new subanalysis of the STRIDE trial.
- Ozempic improved strolling distance in sufferers with kind 2 diabetes and early peripheral artery illness, no matter baseline diabetes traits.
CHICAGO — Semaglutide 1 mg improves strolling distance in sufferers with early peripheral artery illness and kind 2 diabetes, no matter baseline diabetes length, HbA1c, BMI and concomitant treatment use.
Subodh Verma, MD, PhD, FRCSC, professor of medication, cardiac surgeon and the Canada Analysis Chair in Cardiovascular Surgical procedure at College of Toronto, introduced new insights from the just lately reported STRIDE trial wanting on the impact of semaglutide 1 mg (Ozempic, Novo Nordisk) in sufferers with peripheral artery illness (PAD) and diabetes based mostly on baseline diabetes traits.
Adults with early peripheral artery illness and kind 2 diabetes had improved strolling distance with semaglutide, no matter baseline diabetes traits. Picture: Adobe Inventory
“Present vascular [guidelines], and different pointers globally, have echoed the truth that … discovering options to enhance signs and delay the development of peripheral arterial illness is paramount. The STRIDE trial actually ushers in what we consider to be a completely novel paradigm — a paradigm that has been ignored so far with the evolution of SGLT2 inhibitors and GLP-1 receptor agonists as foundational pillars for [major adverse cardiac event] safety,” Verma stated throughout a press convention on the American Diabetes Affiliation Scientific Classes. “The No. 1 threat issue for peripheral arterial illness is diabetes. Peripheral arterial illness is without doubt one of the most typical and infrequently preliminary manifestations of cardiovascular occasions in folks with diabetes … as they are saying, ‘painful legs, aching coronary heart.’”
As Healio beforehand reported, the STRIDE trial enrolled 792 sufferers with diabetes and early symptomatic PAD (imply age, 68 years; 25% girls). Members had been randomly assigned semaglutide 1 mg or placebo. All sufferers had intermittent claudication and an ankle-brachial index of 0.9 or much less or a toe-brachial index of 0.7 or much less.
Subodh Verma
Semaglutide was discovered to enhance strolling distance in contrast with placebo on this affected person inhabitants. The first endpoint of estimated median ratio to baseline in most strolling distance on a continuing load treadmill at 52 weeks was 1.21 within the semaglutide group in contrast with 1.08 within the placebo group (estimated therapy ratio [ETR], 1.13; 95% CI, 1.06-1.21; P = .0004).For the brand new subanalysis, researchers evaluated the therapy impact of semaglutide vs. placebo, stratified by baseline diabetes traits together with HbA1C, diabetes length and diabetes depth.
Median diabetes length was 12.2 years, baseline common HbA1c was 7.1% and baseline BMI was 28.7 kg/m2. Two-thirds of sufferers had been taking an SGLT2 inhibitor and 31.7% had been utilizing insulin.
The researchers reported comparable enhancements in most strolling distance amongst these assigned semaglutide no matter:
- diabetes length (ETR, 1.15 for < 10 years vs. 1.13 for 10 years; P = .8);
- BMI (ETR, 1.12 for < 30 kg/m2 vs. 1.16 for 30 kg/m2 P = .58);
- HbA1c (ETR, 1.13 for < 7% vs. 1.13 for 7%; P = .99);
- SGLT2 inhibitor use (ETR, 1.15 to be used vs. 1.15 for nonuse; P = .954); and
- insulin use (ETR, 1.14 to be used vs. 1.17 nonuse; P = .723).
As well as, semaglutide improved pain-free stroll distance throughout all subgroups (P for all > 0.1).
The security profile of semaglutide was constant throughout all subgroups, in response to the outcomes.
The examine was concurrently printed in Diabetes Care.
“We do not consider that weight is driving this profit; there was a really small 4 kg weight reduction on this inhabitants. There’s actually no correlation between weight and outcomes right here,” Verma stated throughout the presentation. “We expect this marks a transformative change within the administration of peripheral arterial illness, and it strikes the sphere ahead, after 25 years, for an issue that’s debilitating for sufferers.”
Reference:
Sources/Disclosures
Collapse
Rasouli N, et al. Symposium – Diabetes and peripheral artery illness – Evolving position of GLP-1 RA and new insights from the STRIDE trial. Offered at: American Diabetes Affiliation’s Scientific Classes; June 20-23, 2025; Chicago.
Disclosures:
The STRIDE trial was supported by Novo Nordisk. Verma studies varied monetary relationships, together with with Novo Nordisk. Please see the examine for the authors’ related monetary disclosures.
